Inhibikase Therapeutics (IKT) Operating Income Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Operating Income Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | 1,386.07% |
| 10 | Inhibikase Therapeutics | 401.48 Mn | 231.11 Mn | - | -22.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.22% |
| Dec 31, 2025 | -6.55% |
| Sep 30, 2025 | -119.11% |
| Jun 30, 2025 | -114.48% |
| Mar 31, 2025 | -205.25% |
| Dec 31, 2024 | -193.60% |
| Sep 30, 2024 | -22.20% |
| Jun 30, 2024 | 18.57% |
| Mar 31, 2024 | -1.43% |
| Dec 31, 2023 | -1.58% |
| Sep 30, 2023 | -5.67% |
| Jun 30, 2023 | -33.67% |
| Mar 31, 2023 | -1.60% |
| Dec 31, 2022 | 14.01% |
| Sep 30, 2022 | -0.94% |
| Jun 30, 2022 | -76.53% |
| Mar 31, 2022 | -76.77% |
| Dec 31, 2021 | -319.83% |
| Sep 30, 2021 | -573.64% |
| Jun 30, 2021 | -534.99% |